Annual Meeting ProceedingsAmerican Society of Clinical Oncology, 2004 |
From inside the book
Results 1-3 of 87
Page 38
... activity in a number of malignancies . Preclinically , FTIs have synergistic activity when used with tamoxifen in breast cancer cell lines . We conducted a phase I trial using tipifarnib with tamoxifen in patients with hormone ...
... activity in a number of malignancies . Preclinically , FTIs have synergistic activity when used with tamoxifen in breast cancer cell lines . We conducted a phase I trial using tipifarnib with tamoxifen in patients with hormone ...
Page 306
... activity in lung and head and neck cancer , but its clinical activity in ACRC is still unknown . We designed this trial to assess the safety and efficacy of Iressa in association with CAP - OXA regimen as first - line treatment in pts ...
... activity in lung and head and neck cancer , but its clinical activity in ACRC is still unknown . We designed this trial to assess the safety and efficacy of Iressa in association with CAP - OXA regimen as first - line treatment in pts ...
Page 414
... activity of TS in 68 RCC and evaluated the association between the level of TS activity and the stage / grade of RCC . The relationship between TS activity in primary cultured RCC cell lines and their sensitivity to 5 - FU was also ...
... activity of TS in 68 RCC and evaluated the association between the level of TS activity and the stage / grade of RCC . The relationship between TS activity in primary cultured RCC cell lines and their sensitivity to 5 - FU was also ...
Contents
data is that preoperative breast biopsy does not cause artificial tumour cell | 22 |
Side Irradiated | 33 |
A novel tumor marker of potential utility in metastatic | 46 |
Copyright | |
20 other sections not shown
Other editions - View all
Common terms and phrases
activity administered adverse events analysis anthracycline antibody antitumor apoptosis assessed Background baseline biopsy breast cancer breast cancer patients Cancer Center Cancer Institute capecitabine carboplatin carcinoma clinical trial cohort colorectal cancer combination Conclusions correlated cycles diarrhea docetaxel dose level doxorubicin drug effects efficacy EGFR enrolled erlotinib evaluated follow-up G-CSF gefitinib gemcitabine gene Germany grade HER2 Hospital Imatinib infusion inhibition inhibitor irinotecan liver median age metastatic metastatic breast cancer Methods mg/m² months neoadjuvant neutropenia observed Oncology oral overall survival oxaliplatin paclitaxel patients pts patients received patients with advanced pharmacokinetic phase II study phase II trial plasma Poster Discussion Poster Session primary prior progression protein pts received radiotherapy randomized range receptor recurrence regimen respectively response rate Results rituximab significant solid tumors stable disease surgery tamoxifen taxane therapy tolerated toxicity trastuzumab treated treatment tumor tumor cells University vaccine VEGF vinorelbine weeks women